New Age Alpha Advisors LLC Purchases Shares of 2,842 TransMedics Group, Inc. (NASDAQ:TMDX)

New Age Alpha Advisors LLC acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,842 shares of the company’s stock, valued at approximately $177,000.

Other hedge funds also recently modified their holdings of the company. Hager Investment Management Services LLC bought a new stake in TransMedics Group during the 4th quarter worth approximately $33,000. Sachetta LLC bought a new stake in shares of TransMedics Group during the fourth quarter worth $40,000. AlphaQuest LLC acquired a new stake in shares of TransMedics Group in the fourth quarter valued at $52,000. Quarry LP raised its holdings in shares of TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after buying an additional 312 shares during the last quarter. Finally, National Bank of Canada FI lifted its position in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after buying an additional 262 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Up 7.1 %

Shares of NASDAQ TMDX opened at $73.11 on Thursday. The firm has a 50 day moving average price of $69.76 and a 200 day moving average price of $86.43. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market cap of $2.46 billion, a P/E ratio of 77.78 and a beta of 2.12. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Robert W. Baird dropped their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Piper Sandler reduced their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.